MS Pharma Signs an Exclusive License Agreement with Bioeq to Commercialize FYB201 (biosimilar, ranibizumab) in MENA Region
Shots:
- Under an exclusive agreement, MS Pharma will initiate the registration procedures in MENA shortly & will be responsible for the registration and commercialization of FYB201 in the licensed countries
- Bioeq & Formycon collaborated to develop FYB201 where Bioeq will be responsible for the development and supply of biosimilar & is currently under registration in the EU & the US. Additionally, Formycon will participate in the commercialization revenues of FYB201 in all territories, following approval of FYB201
- Ranibizumab, a biosimilar to Novartis’ Lucentis is indicated for the treatment of AMD and other serious eye conditions
Ref: Formycon | Image: Formycon
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
